Furthermore, network analysis of significantly altered proteins in bladder cancer revealed CDK2 as one central regulator mediating cisplatin resistance [42], with the consequence that targeting the CDK–cyclin axis may restore cisplatin-sensitivity [43]. This evidence concerns the gene CDK2 and urinary bladder carcinoma.